Healthcare job growth driven by ambulatory settings

By January, there were 2.5 million more healthcare jobs than at the start of the Great Recession, with nearly two-thirds of that growth coming from ambulatory care settings.

Ani Turner, deputy director of Altarum Institute’s Center for Sustainable Health Spending, and her coauthors examined the nature of the employment growth in a Health Affairs blog. Health care jobs overall grew by 19 percent, with a growth rate of 11 percent in hospitals. Within ambulatory care, home health had the fastest rate of job growth at 49 percent, physician offices grew by 17 percent and jobs in all other ambulatory settings grew by 34 percent.

“These patterns of growth have shifted the mix of jobs by delivery setting slightly since 2007,” Turner and his coauthors wrote. “Currently, hospitals employ about one-third of health care jobs, down from 35 percent in 2007. The share of health jobs in ambulatory care settings is 46 percent, up from 42 percent in 2007, and nursing and residential care represents the remaining 21 percent, down from 22 percent in 2007.”

Read the full article below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.